Caption Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-34,530
Closed -$390K 1794
2022
Q2
$390K Buy
+34,530
New +$693K 0.01% 1126
2022
Q1
Sell
-3,790
Closed -$99K 1870
2021
Q4
$99K Buy
+3,790
New +$114K ﹤0.01% 1481
2021
Q1
Sell
-20
Closed -$792 1330
2020
Q4
$0 Buy
+20
New +$579 ﹤0.01% 1207
2019
Q1
Sell
-5,500
Closed -$126K 707
2018
Q4
$126K Buy
+5,500
New +$155K 0.01% 415

Other funds holding RIGL

Caption Management's RIGL Position: Q3 2022 in Review

Caption Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2022, closing a stake of 34,530 shares — an estimated $390K sold.

Caption Management first reported a position in RIGL in Q4 2018 and held it in 4 quarters. The position peaked at $390K in Q2 2022. 138 funds tracked by Wall St. Rank hold RIGL as of Q3 2022.

  • Caption Management reported no remaining Rigel Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Caption Management sold 34,530 Rigel Pharmaceuticals shares in Q3 2022, an estimated $390K.
  • Caption Management first reported a position in Rigel Pharmaceuticals in Q4 2018 and held it in 4 quarters.
  • Caption Management's Rigel Pharmaceuticals position peaked at $390K in Q2 2022.
  • 138 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2022.

Based on Caption Management's 13F filing for Q3 2022, filed 14 Nov 2022.